Published in Expert Rev Anticancer Ther on January 01, 2012
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
The emerging genomic landscape of endometrial cancer. Clin Chem (2013) 0.94
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2016) 0.78
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clin Cancer Res (2014) 0.77
Inferring pathway dysregulation in cancers from multiple types of omic data. Genome Med (2015) 0.76
Improved i.p. drug delivery with bioadhesive nanoparticles. Proc Natl Acad Sci U S A (2016) 0.76
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 6.26
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Endometrial carcinoma. N Engl J Med (1996) 3.31
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res (2004) 2.77
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res (2009) 2.68
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer (2006) 2.67
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res (1990) 2.55
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 2.32
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem (1997) 1.91
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch (2004) 1.80
Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol (2008) 1.74
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer (2005) 1.60
Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer (2003) 1.57
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res (2003) 1.54
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer (2006) 1.41
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol (2005) 1.40
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer (2005) 1.39
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet (2008) 1.38
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.36
Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol (1992) 1.34
Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol (2004) 1.33
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol (2005) 1.31
Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res (2002) 1.27
Rare uterine cancers. Lancet Oncol (2005) 1.25
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol (2005) 1.20
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer (2006) 1.16
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer (2004) 1.14
HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol (1992) 1.11
Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res (2003) 1.11
The management of serous papillary uterine cancer. Curr Opin Oncol (2006) 1.11
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer (2010) 1.08
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol (1991) 1.07
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther (2010) 1.03
Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol (2010) 1.02
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res (2005) 1.02
Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer (2006) 1.00
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther (2007) 0.99
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol (2005) 0.96
Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol (2005) 0.95
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys (2005) 0.95
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol (2010) 0.92
Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res (2005) 0.92
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer (2007) 0.89
Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol Oncol (2005) 0.89
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer (2009) 0.88
High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol (2006) 0.87
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer (2011) 0.86
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol (2010) 0.86
Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. Gynecol Oncol (2005) 0.84
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer (2010) 0.84
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol Oncol (2008) 0.83
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer (2009) 0.82
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am J Obstet Gynecol (2006) 0.81
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer (2011) 0.81
The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol (2005) 0.80
Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet (2004) 0.77
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol (2003) 1.65
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis (2002) 1.58
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res (2003) 1.52
Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res (2003) 1.46
HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol (2003) 1.43
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol (2005) 1.40
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol (2006) 1.40
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer (2009) 1.38
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol (2007) 1.37
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol (2003) 1.31
MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol (2010) 1.29
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.28
Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol (2010) 1.27
The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol (2008) 1.26
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther (2013) 1.23
Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol (2005) 1.19
Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer (2003) 1.19
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer (2010) 1.16
Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol (2003) 1.16
Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev (2002) 1.09
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer (2011) 1.06
Serum amyloid A: a novel biomarker for endometrial cancer. Cancer (2010) 1.05
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol (2013) 1.05
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev (2011) 1.04
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther (2010) 1.03
Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol (2004) 1.02
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology (2011) 1.01
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol (2010) 1.00
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol (2007) 0.98
Early stage uterine serous carcinoma: management updates and genomic advances. Gynecol Oncol (2013) 0.98
Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: a comparison. Cancer (2003) 0.97
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol (2005) 0.96
Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol (2007) 0.94
Sexuality and intimacy after gynecological cancer. Maturitas (2010) 0.94
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer (2011) 0.94
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol (2010) 0.93
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer (2010) 0.92
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol (2010) 0.92
Local administration of interleukin-11 ameliorates intestinal radiation injury in rats. Cancer Res (2007) 0.92
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol (2011) 0.92
Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol (2008) 0.91
Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int J Cancer (2003) 0.91
Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol (2007) 0.91
Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer. Gynecol Oncol (2003) 0.91
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol (2012) 0.91
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer (2013) 0.90
A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. Int J Gynecol Cancer (2015) 0.90
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med (2014) 0.90
Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol (2005) 0.90
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol (2011) 0.90
Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol (2011) 0.89
Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci (2013) 0.89
Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med (2002) 0.89
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis (2013) 0.88
Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer (2014) 0.88
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol (2013) 0.88
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol (2013) 0.87
A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother (2008) 0.87
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Arch Pathol Lab Med (2014) 0.87
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol (2012) 0.86
Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun (2006) 0.86
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer (2011) 0.86
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res (2011) 0.86
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol (2009) 0.86
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol (2010) 0.86